Skip to main content

Table 1 Characteristics of patients with advanced NSCLC who received nivolumab monotherapy but discontinued it for a reason other than tumor progression

From: Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer

Patient No. Sex Histological type EGFR mutation ALK fusion gene Treatment regimen prior to nivolumab Nivolumab treatment
Age at initiation (years) ECOG PS at initiation Number of doses Responsea Reason for discontinuationb
1 F Adenocarcinoma wt wt PEM + BEV 79 1 1 NE Bone fraction
2 M Pleomorphic wt wt CBDCA + PTX + BEV, DTX 60 1 3 PR irAE (grade 5 encephalitis)
3 M Adenocarcinoma wt wt CBDCA + PEM 61 1 6 SD Rejection
4 M Squamous wt wt CBDCA + PTX, VNR, CBDCA + S-1 68 0 2 PR irAE (grade 2 pneumonitis)
5 M NOS wt wt CBDCA + PTX + TRT, PEM + BEV 55 2 1 NE irAE (grade 2 pneumonitis)
6 M Squamous wt wt CBDCA + PTX 78 1 1 NE irAE (grade 2 pneumonitis)
7 M Adenosquamous wt wt GEM + VNR, PEM, DTX, PEM + BEV 90 1 1 SD Infection
8 M Adenocarcinoma wt wt CBDCA + PTX + TRT, CBDCA + PEM, DTX 75 1 31 SD irAE (grade 2 pneumonitis)
9 M Squamous wt wt CDDP + S-1, CBDCA + nabPTX 67 1 2 PR irAE (grade 3 dermatitis)
10 M Adenosquamous wt wt TRT, DTX 83 1 11 PR Heart failure
11 F Adenocarcinoma wt wt PEM, DTX 79 1 8 SD irAE (grade 3 arthritis)
12 M Squamous wt wt CBDCA + nabPTX 79 2 3 SD irAE (grade 1 pneumonitis)
13 M Adenocarcinoma wt wt CBDCA + PEM 69 2 2 SD irAE (grade 2 pneumonitis)
14 M Adenocarcinoma L858R wt CBDCA + PEM, Afatinib, DTX, Erlotinib + BEV, nabPTX, GEM, VNR 64 1 1 NE irAE (grade 5 pneumonitis)
15 M Adenocarcinoma NE NE CDDP + PEM 59 1 1 NE irAE (grade 5 pneumonitis)
16 F Squamous wt wt CBDCA + S-1 76 0 2 NE irAE (grade 3 pneumonitis)
17 M Squamous NE NE TRT, CBDCA + S-1, VNR 68 2 5 SD Rejection
  1. NSCLC non-small cell lung cancer, EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, ECOG PS the Eastern Cooperative Oncology Group performance status, F female, M male, NOS not otherwise specified, wt. wild type, NE not evaluable, PEM pemetrexed, BEV bevacizumab, CBDCA carboplatin, PTX paclitaxel, DTX docetaxel, VNR vinorelbine, TRT thoracic radiotherapy, GEM gemcitabine, CDDP cisplatin, nabPTX nab-paclitaxel, PR partial response, SD stable disease, irAE immune-related adverse event
  2. aThe responses were classified by the Response Evaluation Criteria in Solid Tumors 1.1
  3. bAdverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0